Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
LIVONIA, Mich., Sept. 22, 2016 -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that Mina Sooch, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held at the Sofitel New York Hotel, on Tuesday, September 27.
| Presentation Details: | |
| Date: | Tuesday, September 27 |
| Time: | 2:00pm Eastern Time |
| Location: | Sofitel New York Hotel, Trocadero Room |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700
